Burning Rock Biotech
BNR
32 hedge funds and large institutions have $46.2M invested in Burning Rock Biotech in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.
0.15% more ownership
Funds ownership: 2.45% → 2.6% (+0.15%)
6% less funds holding
Funds holding: 34 → 32 (-2)
24% less capital invested
Capital invested by funds: $60.8M → $46.2M (-$14.7M)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.27M |
| 2 |
Millennium Management
New York
|
+$335K |
| 3 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$55.1K |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$29.1K |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$771K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$557K |
| 3 |
Morgan Stanley
New York
|
-$371K |
| 4 |
Barclays
London,
United Kingdom
|
-$289K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$138K |
BNR Hedge Fund Activity: Q2 2023 in Review
32 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q2 2023, worth a combined $46.2M — down 24% from $60.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BNR and 4 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Kynam Capital Management, adding an estimated $1.27M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $771K sold.
- 32 institutional investors held Burning Rock Biotech (BNR) as of Q2 2023, down from 34 in Q1 2023.
- Funds reported $46.2M of Burning Rock Biotech stock for Q2 2023, down 24% quarter-over-quarter.
- 4 funds opened new Burning Rock Biotech positions in Q2 2023 and 6 closed out, a net change of -2 holders.
- The largest Burning Rock Biotech buyer in Q2 2023 was Kynam Capital Management, an estimated $1.27M added.
- The largest Burning Rock Biotech seller in Q2 2023 was Assenagon Asset Management, an estimated $771K sold.
Based on aggregated 13F filings for Q2 2023.